On August 10, 2021, NuChem Sciences, a contract medical research company, announced the completion of the acquisition of OmegaChem. Together, they form the largest actor in the Canadian contract chemical drug discovery research organization sector.
The transaction was supported by a total debt and equity investment of $37.6M Canadian by the Fonds de solidarité FTQ ($17.4M), Investissement Québec ($10.1M) and BDC Capital ($10.1M).
The two companies and their approximately 100 employees will continue their activities in their respective niches, but will benefit from their unified business card and from sharing their good practices.
A Fasken team composed of Vincent Girard, Marie Carole Tétrault, Michaëlle Guilbault, Philippe Beauchamp, Frédéric St-Jean, Geneviève Laliberté, Terry Kyle Lapierre, Émilie Sylvain Jacques and Cathie Jones represented NuChem and its shareholders in connection with this acquisition.